
Keywords: AML; acute myeloid leukemia; CAK; CDK-activating kinase; CDK; cyclin-dependent kinases; CLL; chronic lymphocytic leukemia; CT; RNA polymerase II C-terminal domain; DLT; dose-limiting toxicities; DSIF; DRB-sensitivity inducing factor; ER; estrogen Receptor